Table 2 List of all active, completed or terminated clinical trials of mRNA CAR-T cells in cancer therapy
Sponsor | Therapy | Indication | ClinicalTrial.gov identifier (phase) | Combination | Opened | Status |
|---|---|---|---|---|---|---|
Cartesian Therapeutics | BCMA CAR-T cells (Descartes-08) | Multiple myeloma | NCT03448978 (I) | Fluodarabine and cyclophosphamide pretreatment | 2018 | Recruiting [156] |
The Third Affiliated Hospital of Guangzhou Medical University | NKG2D-ligand targeting CAR-NK cells | Solid tumors | NCT03415100 (I) | IL-2 | 2018 | Unknown [157] |
University of Pennsylvania | Mesothelin CAR-T cells | Malignant pleural mesothelioma | NCT01355965 (I) | None | 2011 | |
Metastatic PDAC | NCT01897415 (I) | None | 2013 | |||
c-MET CAR-T cells | Metastatic breast cancer, TNBC | NCT01837602 (I) | None | 2013 | Completed [161] | |
Melanoma, breast cancer | NCT03060356 (I) | None | 2016 | Terminated (lack of funding) | ||
CD19 CAR-T cells | Hodgkin lymphoma | NCT02277522 (I) | Interval cyclophosphamide [162] | 2014 | Terminated (inability to meet enrollment goal) [163] | |
NCT02624258 (I) | Interval cyclophosphamide [162] | 2015 | Terminated (PI’s decision) [163] | |||
CD123 CAR-T cells | Relapsed or refractory AML | NCT02623582 (I) | Cyclophosphamide pretreatment | 2015 | Terminated (lack of funding) [164] |